"10.1371_journal.pone.0052564","plos one","2012-12-20T00:00:00Z","Ludovic Belle; France Bruck; Jacques Foguenne; André Gothot; Yves Beguin; Frédéric Baron; Alexandra Briquet","Hematology Research Unit, Giga-I3, University of Liège, Liège, Belgium; Department of Laboratory Hematology and Immuno-Hematology, Centre hospitalier universitaire de Liège, Liège, Belgium; Department of Medicine, Division of Hematology, Centre hospitalier universitaire de Liège, Liège, Belgium","Conceived and designed the experiments: LB AB F. Baron AG YB. Performed the experiments: LB AB F. Bruck JF. Analyzed the data: LB AB. Contributed reagents/materials/analysis tools: YB AG. Wrote the paper: LB AB F. Baron.","LB, F. Baron and YB have received travel grants from Novartis Pharmaceuticals. YB received unrestricted research grant from Novartis Pharmaceuticals, although these grants were not related to this study. Novartis provided imatinib and nilotinib for this study, and markets both products. Novartis received the final draft of the publication prior to submission since they kindly provided the authors with imatinib and nilotinib, and suggested a number of minor edits to the manuscript. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","12","Ludovic Belle","LB",7,TRUE,3,3,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
